FindTrial
Sign In

Investigating the inhibitory effect of 4-octyl itaconate on Th17 cell differentiation in human peripheral blood mononuclear cells provides a theoretical basis for its potential translation into a clinical therapeutic for dry eye disease

Therapeutic effect of 4-octyl itaconate on autoimmune dry eye disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121612
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune dry eye disease

Interventions

Vehicle group and 4-OI group:None
4-OI group:None

Sponsors

Tianjin Medical University Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Patients with dry eye disease (tear film break-up time = 1).

Exclusion criteria

Exclusion criteria: 1.Any patients deemed unsuitable for inclusion by the investigators.

Design outcomes

Primary

MeasureTime frame
Th17 cell–associated markers;—

Countries

China

Contacts

Public ContactRuihua Wei

Tianjin Medical University Eye Hospital

weirhua2009@126.com+86 139 2068 5016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026